Prophase labs announces financial results for the three months ended march 31, 2025

Highlights multiple significant potential liquidity events anticipated within the next few months completes significant reductions in overhead and expenses be-smart esophageal cancer test study has been submitted in the journal of clinical gastrointestinal hepatology company to hold a virtual conference call tuesday, may 20, 2025, at 10:00 am et garden city, ny, may 20, 2025 (globe newswire) -- prophase labs inc. (nasdaq: prph), (the “company” or “prophase”) a next generation biotech, genomics and consumer products company, today reported its financial and operational results for q1 ended march 31, 2025, and outlined significant strategic corporate developments. ted karkus, ceo of prophase labs, will present to shareholders today, may 20, 2025, at 10:00 a.m.
PRPH Ratings Summary
PRPH Quant Ranking